ClinicalTrials.gg
RecruitingNCT07459504Updated Nov 13, 2026

SMART Diets for MASLD

A Phase 2 interventional study of Essential Amino Acids Supplementation intervention and Low sugar diet in Metabolic-dysfunction Associated Steatotic Liver Disease, sponsored by Michigan State University. Recruiting at 1 site in United States. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Michigan State University · Phase 2, Interventional, and Treatment

How we know

Updated Nov 13, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
11 Years to 17 Years
Sex
All
01

Study summary

This phase 2 trial is a single-site sequential, multiple assignment, randomized trial (SMART) to test and construct a high-quality adaptive intervention of essential amino acids (EAA) and/or Low Sugar Diet for children with metabolic dysfunction associated steatotic liver disease (MASLD) and increased cardiometabolic risk. The basis for the trial includes high-quality pilot data in both EAA for hepatic steatosis and a low sugar diet for hepatic steatosis. In the trial, children aged 11-17 years old will be eligible to participate if their BMI is greater than or equal to 95th% at baseline and hepatic steatosis is greater than or equal to 8% at baseline by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) because this is the most common age group diagnosed with metabolic-dysfunction associated steatotic liver disease.

Read the detailed description

Metabolic-dysfunction associated steatotic liver disease is defined as the presence of abnormal hepatic stored triglycerides (hepatic steatosis), with one or more of 5 cardiometabolic factors (increased body mass index or waist circumference, hyperglycemia, hypertriglyceridemia, or low HDL) and no other chronic liver disease. Pediatric hepatic steatosis is central to long-term metabolic and cardiovascular health because of the relation of hepatic steatosis to the development of other major diseases. Hepatic steatosis limits the normal metabolic role of insulin and plays a key role in the future development of the metabolic syndrome, and is the strongest predictor for the development of type 2 diabetes.

02

Conditions studied

  • Metabolic-dysfunction Associated Steatotic Liver Disease

Keywords

  • MASLD
  • Adolescents
  • Liver
  • Sugar
  • Amino acid supplement
03

In context

Lead sponsor

Michigan State University is the lead sponsor of 143 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children 11 to 17-years-old at the time of consenting
  • Hepatic Steatosis by MRI greater than or equal to 8% on baseline MRI
  • At least 1 of the following cardiometabolic risk factors: greater than or equal to 85th percentile for age/sex or WC greater than 95th percentile, Abnormal cholesterol or triglyceride levels, Blood pressure BP greater than or equal to 95th percentile OR greater than or equal to 130/80 and/or signs of insulin resistance (Acanthosis Nigricans OR HOMA-IR of greater 2.0 and greater 2.6 in prepubertal and pubertal children, respectively, Fasting Insulin Level of 10 pIU/mL in prepubertal children and of 17 pIU/mL and 13 pIU/mL in pubertal girls and boys, respectively, OR Prediabetes)
  • greater than or equal to 40 U/L
  • Currently consumes greater than or equal to 2 eight-ounce sugar drinks (or juice) per week.
  • Patients of agrees to use adequate one or more effective methods of (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  • Patients who are taking medications that can affect insulin (e.g., metformin, ), most be on a stable dosage for at least 3 months prior to enrollment of the trial.
  • Written from parent or legal guardian, assent from child.

Exclusion criteria

Exclusion Criteria:

  • Patients with Diagnosed Type 2 or Type 1 Diabetes Mellitus (T2DM) or of >6.5 mg/dL at baseline
  • Patients diagnosed with or suspected to have a chronic liver disease other than MASLD by screening labs or evaluation (i.e , viral). Screening labs are defined as: surface antigen, virus total antibody, IgG, ceruloplasmin, and alpha 1 antitrypsin phenotype.
  • Patients unable to complete MRI or Labs required for the study.
  • Current participation in another clinical trial
  • Current participation in a weight loss program or obesity treatment program or clinic
  • Cancer or history of cancer within 5 years
  • Severe illness that required hospitalization in the last 60 days
  • Use of medications known to cause liver steatosis (TPN, amiodarone, chronic oral , etc.)
  • Patients with implanted metal devices that are not compatible with magnetic resonance imaging (MRI).
  • Intellectual disability or major psychiatric disorder limiting informed assent
  • Clinical evidence of cirrhosis or advanced liver disease by any one of the following abnormal labs: ( less than 10 g/dL, White blood cell less than 3,500 cells/mm, less than 1,500 cells/mm3 of blood, less than 130,000 cells/mm3 of blood, Direct greater than 1.0 mg/dL)
  • Elevated total bilirubin except if known to have Gilbert's syndrome and direct bilirubin in normal range.
  • Albumin less than 3.2 g/dL
  • A history of (INR) greater than 1.4
  • or ALT greater than 250 IU/dL.
  • Compensated or decompensated cirrhosis with evidence of portal hypertension.
  • Patients is pregnant or breastfeeding.
  • Patients who have been enrolled in a recent clinical trial and had the last dose of product within 30 days or 5 half-lives of the study drug, whichever is longer.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    Essential Amino Acids Supplementation

    The essential amino acid supplement contains the following formulation: histidine, isoleucine, leucine, lysine, phenylalanine, threonine, and valine. EAA, also called AMS2392 has been shown to decrease hepatic steatosis and lower circulating very-low-density lipoprotein triglyceride (VLDL-TG) concentrations through one or more of the following mechanisms: decreasing de novo lipogenesis; increasing hepatic and systemic fatty acid oxidation; increasing triglyceride secretion from the liver in the form of VLDL-TG; and increasing clearance of circulating VLDL-TG via activation of lipoprotein lipase.

    Drug: Essential Amino Acids Supplementation intervention

  • Active comparator
    Low Sugar Diet

    The Low Sugar Diet uses the adapted and extended Social Cognitive Theory (SCT) guided low sugar intervention that the Emory team previously developed. The registered dietitian nutritionist (RDN) helps families to identify foods high in sugar and to identify acceptable replacements in order to remove foods and drinks high in free sugar from the home and replacement with low or no free sugar containing similar foods.

    Other: Low sugar diet

Interventions

  • DrugEssential Amino Acids Supplementation intervention

    EAA supplement contains the following formulation: histidine, isoleucine, leucine, lysine, phenylalanine, threonine, and valine

    Also known as: EAA, AMS2392

  • OtherLow sugar diet

    The Low Sugar Diet uses the adapted and extended Social Cognitive Theory (SCT) guided low sugar intervention. The registered dietitian nutritionist (RDN) helps families to identify foods high in sugar and to identify acceptable replacements in order to remove foods and drinks high in free sugar from the home and replacement with low or no free sugar containing similar foods.

06

What researchers measure

Primary outcomes

  1. Change in hepatic steatosis

    Change in hepatic steatosis by magnetic resonance imaging (MRI)

    Time frame: Baseline to 24 weeks

Secondary outcomes

  1. Change in fasting triglyceride

    Change in triglyceride in mg/dL

    Time frame: Baseline, 12 and 24 weeks

  2. Change in HDL

    Change in HDL mg/dL

    Time frame: Baseline, 12 and 24 weeks

  3. Change in VLDL-triglyceride

    Very-low-density-lipoprotein triglyceride

    Time frame: Baseline, 12 and 24 weeks

  4. Change in Waist circumference

    Change in Waist circumference in cm

    Time frame: Baseline, 12 and 24 weeks

  5. Change in body weight

    Change in weight in kilograms

    Time frame: Baseline, 12 and 24 weeks

  6. Change in BMI Z Score

    Change in body mass index z-score

    Time frame: Baseline, 12 and 24 weeks

  7. Change in Alanine Aminotransferase (ALT)

    Change in ALT

    Time frame: Baseline, 12 and 24 weeks

  8. Aspartate Aminotransferase (AST)

    Change in AST

    Time frame: Baseline, 12 and 24 weeks

  9. Gamma glutamyl transferase (GGT)

    Change in GGT

    Time frame: Baseline, 12 and 24 weeks

  10. Systolic blood pressure

    Change in systolic blood pressure mg/dL

    Time frame: Baseline, 12 and 24 weeks

  11. Diastolic blood pressure

    Change in diastolic blood pressure (mg/dL)

    Time frame: Baseline, 12 and 24 weeks

  12. Hemoglobin A1c

    Change in hemoglobin A1c

    Time frame: Baseline, 12 and 24 weeks

  13. HOMA-IR

    Change in homeostatic model assessment of insulin resistance (HOMA-IR)

    Time frame: Baseline, 12 and 24 weeks

  14. Adverse events

    Number of adverse events compared between arms of the study

    Time frame: Baseline, 12 and 24 weeks

  15. Percent responders

    Percent of participants who reduce hepatic steatosis in the group that start with low sugar diet compared to the group that starts with EAA intervention

    Time frame: Baseline to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The proposed research will include data from approximately 102 participants at up to 3 time-points. The final scientific datasets will include intervention assignment, anthropometrics, laboratory and imaging data. All protected health information and personally identified information will be removed. The study dates will be removed. Scientific data from the primary and secondary endpoints, along with a detailed data dictionary, and study protocols will be made available on a data repository such as Emory DataVerse. Genetic information for participants will not be made available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The IPD will be available within one year of the publication of the results of the trial and will be hosted for at least 2 years.

Access criteria: The Emory DataVerse is an open-source web application available to registered users.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Dec 2029, 37 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Mar 9, 2026
StartActual
Nov 5, 2026was Jun 2026
Primary completionEst.
Dec 26, 2029
CompletionEst.
Dec 26, 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Nov 5, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Jun 2026→Nov 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07459504
Responsible party
Miriam B. Vos (Principal Investigator, Michigan State University) — Principal investigator
First posted
Mar 9, 2026
Start date
Nov 5, 2026
Primary completion
Dec 26, 2029 (estimated)
Completion
Dec 26, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Miriam B Vos, MD, MSPH
Contact
miriam.vos@msu.edu
616-267-2100
Miriam B Vos, MD, MSPH
principal investigator · Michigan State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion